Pelargonium Extract EPs 7630 in the Treatment of Human Corona Virus-Associated Acute Respiratory Tract Infections – A Secondary Subgroup-Analysis of an Open-Label, Uncontrolled Clinical Trial

Background: Experience in treating human coronavirus (HCoV) infections might help to identify effective compounds against novel coronaviruses. We therefore performed a secondary subgroup-analysis of data from an open-label, uncontrolled clinical trial published 2015 investigating the proanthocyanidin-rich Pelargonium sidoides extract EPs 7630 patients with common cold. Methods: 120 cold and at least 2 out 10 symptoms received one film-coated 20 mg tablet thrice daily for days uncontrolled, interventional multicentre (ISRCTN65790556). At baseline, viral nucleic acids were detected by polymerase chain reaction. Common cold-associated treatment satisfaction evaluated after 5 end. Based on proof acids, we compared course disease or without HCoV infection. Results: In 61 patients, detected. Of these, 23 (37.7%) tested positive (HCoV subset) 38 (62.3%) other viruses only (non-HCoV subset). Patients both subsets showed significant improvement already treatment, although observed change tended be more pronounced subset. end, than 80% groups completely recovered majorly improved. subsets, less 22% took concomitant paracetamol antipyresis. The mean number patients’ off work school/college was similar (0.9 ± 2.6 subset vs 1.3 2.8 non-HCoV groups, most satisfied very treatment. Conclusion: outcomes confirmed infection as favourable infections. As this conducted before pandemic, there is currently no evidence trials efficacy SARS-CoV-2 Dedicated non-clinical studies are required elucidate potential early